Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ).
Shanghai Junshi Biosciences has announced that a planned shareholding reduction by substantial shareholder Shanghai Tanying Investment Partnership (LP), which held 5.79% of the company’s total share capital in A shares, has reached its expiry without any implementation. The shares in question were pre-IPO holdings whose lock-up had been lifted in July 2021, and the lapse of the reduction plan without sales suggests no immediate change in the company’s ownership structure or trading dynamics, providing short-term stability for existing shareholders while reflecting Shanghai Tanying’s decision not to execute its liquidity plan within the designated period.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$26.00 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a China-based biopharmaceutical company listed in Hong Kong and on the STAR Market in Shanghai. It focuses on the research, development and commercialization of innovative biologic therapies, with its share capital split between A shares on the Shanghai Stock Exchange and H shares in Hong Kong, attracting both domestic and international investors.
Average Trading Volume: 3,749,654
Technical Sentiment Signal: Buy
Current Market Cap: HK$40.31B
See more insights into 1877 stock on TipRanks’ Stock Analysis page.